Global Neisseria Meningitides Treatment Market, By Type (A, B, C, W, X, Y, Others), Diagnosis (Blood Test, CSF Test, Culture Test, Others), Treatment (Medication, Vaccination, Others), Population Type (Children, Adults, Paediatrics), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Neisseria Meningitides Treatment Market
Global neisseria meningitides treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR 4.40% in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.
However, an increase in the incidence of meningitis in children also boosts up the market growth. Moreover, rising awareness regarding the vaccination & prevention of meningococcal infections and increased government initiatives and funding for R&D activities also boost up the market growth. But, people who have a highly casual approach in developing countries may hamper the global Neisseria Meningitides treatment market.
Neisseria meningitides is the meningococcus caused by the gram-negative bacteria. It is a serious infection of the thin lining that surrounds the brain and spinal cord. The bacteria are transmitted from person-to-person through droplets of respiratory or throat secretions from carriers. It can cause severe brain damage and is fatal in 50% of cases if untreated. Twelve types of N. meningitides, called serogroups, have been identified, six of which (A, B, C, W, X, and Y) can cause epidemics.
Meningococcal meningitis is observed worldwide but the highest burden of the disease is in the meningitis belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30 000 cases are still reported each year from that area. There are 2 meningococcal vaccines licensed in the United States for use in children and adults against serotypes A, C, Y, and W 135, the MCV4 and the MPSV4.
This neisseria meningitides treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Neisseria Meningitides Treatment Market Scope and Market Size
The neisseria meningitides treatment market is segmented on the basis of type, diagnosis, treatment, population type, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the neisseria meningitides treatment market is segmented into A, B, C, W, X, Y and others.
- On the basis of diagnosis, the neisseria meningitides treatment market is segmented into blood test, CSF test, culture test and others.
- On the basis of treatment, the neisseria meningitides treatment market is segmented into medication, vaccination and others. Medication segment further segmented into antibiotics such as penicillin, ampicillin, ceftriaxone, ciprofloxacin, azithromycin, rifampin and others. Vaccination further segmented into polysaccharide vaccines, conjugate vaccines, protein based vaccine and others.
- On the basis of end-users, the neisseria meningitides treatment market is segmented into hospitals, specialty clinics and others.
- On the basis of population type, the neisseria meningitides treatment market is segmented into children, adults, paediatrics.
- On the basis of distribution channel, the neisseria meningitides treatment market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Neisseria Meningitides Treatment Market Country Level Analysis
Neisseria meningitides treatment market is analysed and market size information is provided by country, type, diagnosis, treatment, population type, end-users and distribution channel as referenced above.
The countries covered in the neisseria meningitides treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the presence of high healthcare expenditure and research & development. Europe accounts the second largest market share due to favourable government support in terms of inclusion of vaccination such as meningococcal C conjugate (MCC) vaccine in national routine immunization schedules. Asia-Pacific is expected to account for the largest market share over coming years for the Neisseria Meningitides treatment market due to increased advancement in the technology as well as growing healthcare expenditure and rising awareness program.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Neisseria meningitides treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Neisseria Meningitides Treatment Market Share Analysis
Neisseria meningitides treatment market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to neisseria meningitides treatment market.
The major players covered in the neisseria meningitides treatment market are Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Merck & Co., Inc., Sanofi, Serum Institute of India Privte limited, Bharat Biotech Limited, CSL Limited, Bavarian Nordic, Takeda Pharmaceutical Limited., Panacea Biotec, Bayer AG, Teva Pharmaceutical Industries Ltd., among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
